PMID- 34145095
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20221207
IS  - 0971-5916 (Print)
IS  - 0975-9174 (Electronic)
IS  - 0971-5916 (Linking)
VI  - 152
IP  - 6
DP  - 2020 Dec
TI  - Direct-acting antiviral agents decrease haemoglobin A1c level in patients with 
      diabetes infected with hepatitis C virus: A systematic review & meta-analysis.
PG  - 562-567
LID - 10.4103/ijmr.IJMR_1088_18 [doi]
AB  - BACKGROUND & OBJECTIVES: Several epidemiologic studies have demonstrated that 
      type 2 diabetes mellitus (T2DM) is more prevalent in patients infected with 
      hepatitis C virus (HCV), and the eradication of HCV has been shown to decrease 
      the risk of T2DM. This meta-analysis was undertaken to see if treatment with 
      direct-acting antiviral (DAA) agents would improve glycaemic control among 
      HCV-infected patients with T2DM. METHODS: A systematic review was conducted using 
      MEDLINE and EMBASE databases since inception to February 2018. Eligible studies 
      must be cohort studies that recruited HCV-infected patients with T2DM and 
      received DAA therapy. The studies must report the change of haemoglobin A1c 
      (HbA1c) level (before vs. after DAA therapy). Patients who achieved sustained 
      virologic response (SVR) were included in the meta-analysis. The mean HbA1c level 
      and standard deviation of participants were extracted from each study to 
      calculate the mean difference (MD). Pooled MD was then calculated using the 
      random effects model. RESULTS: Four cohort studies with 2648 patients were 
      included. Among HCV-infected T2DM patients who achieved SVR with DAA agents, the 
      mean HbA1c level after treatment was significantly lower than the mean HbA1c 
      level before treatment, with the pooled MD of -0.50 per cent (95% confidence 
      interval, -0.66 to -0.34, I([2]) = 77%). The main limitation of this study was 
      the lack of comparison groups. Therefore, it could not be concluded that the 
      observed decreased HbA1c level was a direct result of DAA therapy. INTERPRETATION 
      & CONCLUSIONS: Treatment with DAA agents was found to be associated with a 
      significant reduction of post-treatment HbA1c level compared with pre-treatment 
      HbA1c level among T2DM patients who achieved SVR.
FAU - Lapumnuaypol, Kamolyut
AU  - Lapumnuaypol K
AD  - Department of Internal Medicine, Albert Einstein Medical Center, PA, USA.
FAU - Pisarcik, David
AU  - Pisarcik D
AD  - Department of Internal Medicine, Philadelphia College of Osteopathic Medicine, 
      PA, USA.
FAU - Putthapiban, Prapaipan
AU  - Putthapiban P
AD  - Department of Internal Medicine, Albert Einstein Medical Center, PA, USA.
FAU - Sukhumthammarat, Weera
AU  - Sukhumthammarat W
AD  - Department of Internal Medicine, Albert Einstein Medical Center, PA, USA.
FAU - Wijarnpreecha, Karn
AU  - Wijarnpreecha K
AD  - Department of Gastroenterology, Mayo Clinic Hospital, Gastroenterology - 
      Jacksonville, FL, USA.
FAU - Thongprayoon, Charat
AU  - Thongprayoon C
AD  - Department of Nephrology, Mayo Clinic, Nephrology & Hypertension Rochester, MN, 
      USA.
FAU - Ungprasert, Patompong
AU  - Ungprasert P
AD  - Department of Research & Development, Division of Clinical Epidemiology, Faculty 
      of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Antiviral Agents)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Glycated Hemoglobin
MH  - Hepacivirus
MH  - *Hepatitis C/complications/drug therapy/epidemiology
MH  - *Hepatitis C, Chronic/drug therapy
MH  - Humans
MH  - Sustained Virologic Response
PMC - PMC8224154
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - direct-acting antiviral agents
OT  - haemoglobin A1c
OT  - hepatitis C virus
OT  - meta-analysis
COIS- None
EDAT- 2021/06/20 06:00
MHDA- 2021/07/01 06:00
PMCR- 2020/12/01
CRDT- 2021/06/19 05:40
PHST- 2021/06/19 05:40 [entrez]
PHST- 2021/06/20 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - IndianJMedRes_2020_152_6_562_318242 [pii]
AID - IJMR-152-562 [pii]
AID - 10.4103/ijmr.IJMR_1088_18 [doi]
PST - ppublish
SO  - Indian J Med Res. 2020 Dec;152(6):562-567. doi: 10.4103/ijmr.IJMR_1088_18.